Scholarlink

Background <p>Acute pancreatitis (AP) is a rare but serious complication of intragastric balloon (IGB) therapy. Despite the popularity of IGBs for weight loss, the incidence and risk factors of AP post-IGB insertion are not well understood. This study aimed to identify potential predictors and risk factors of AP in IGB patients.</p> Methods <p>A retrospective time-to-event study was conducted over 7&#xa0;years, encompassing patients who received IGBs between January 2017 and 2024. Cox regression analyses were performed to identify risk factors. The incidence of AP was evaluated as a secondary outcome. Patients were categorized into the AP and non-AP groups at a 1:3 ratio. The Revised Atlanta Classification was used to diagnose AP.</p> Results <p>Among 450 patients with IGB, 25 developed AP, yielding an incidence of 5.56%. The Orbera balloon was associated with a lower AP risk (HR 0.29, 95% CI: 0.09–0.96; <i>P</i> = 0.042). The median time to AP onset was 40&#xa0;days. Higher preprocedural BMI and age &gt; 30&#xa0;years showed a trend toward reduced AP risk, though not statistically significant.</p> Conclusions <p>AP following IGB insertion is uncommon but may be underreported, with substantial variability in onset time. The Orbera balloon demonstrated a protective effect, highlighting the role of balloon type in AP risk. These findings underscore the importance of balloon selection and the need for further prospective studies to confirm these results and optimize AP risk management in IGB patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk Factors for Acute Pancreatitis Following Intragastric Balloon Insertion: A 7-Year Retrospective Cohort Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月14日

查看全文
  • Yousef Yahia,
  • Joud Abuodeh,
  • Prem Chandra,
  • Ethar Mohamed,
  • Anas Zayad,
  • Leen AbuAfifeh

摘要

Background

Acute pancreatitis (AP) is a rare but serious complication of intragastric balloon (IGB) therapy. Despite the popularity of IGBs for weight loss, the incidence and risk factors of AP post-IGB insertion are not well understood. This study aimed to identify potential predictors and risk factors of AP in IGB patients.

Methods

A retrospective time-to-event study was conducted over 7 years, encompassing patients who received IGBs between January 2017 and 2024. Cox regression analyses were performed to identify risk factors. The incidence of AP was evaluated as a secondary outcome. Patients were categorized into the AP and non-AP groups at a 1:3 ratio. The Revised Atlanta Classification was used to diagnose AP.

Results

Among 450 patients with IGB, 25 developed AP, yielding an incidence of 5.56%. The Orbera balloon was associated with a lower AP risk (HR 0.29, 95% CI: 0.09–0.96; P = 0.042). The median time to AP onset was 40 days. Higher preprocedural BMI and age > 30 years showed a trend toward reduced AP risk, though not statistically significant.

Conclusions

AP following IGB insertion is uncommon but may be underreported, with substantial variability in onset time. The Orbera balloon demonstrated a protective effect, highlighting the role of balloon type in AP risk. These findings underscore the importance of balloon selection and the need for further prospective studies to confirm these results and optimize AP risk management in IGB patients.